Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancerResearch in context

Summary: Background: Despite the advent of improved therapeutic options for advanced prostate cancer, the durability of clinical benefits is limited due to inevitable development of resistance. By constitutively sustaining androgen receptor (AR) signaling, expression of ligand-binding domain trunca...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Chiu-Lien Hung, Hao-Hsuan Liu, Chih-Wei Fu, Hsun-Hao Yeh, Tsan-Lin Hu, Zong-Keng Kuo, Yu-Chin Lin, Mei-Ru Jhang, Chrong-Shiong Hwang, Hung-Chih Hsu, Hsing-Jien Kung, Ling-Yu Wang
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2023-04-01
Sarja:	EBioMedicine
Aiheet:	PROTAC AR AR-V7 Castration resistant prostate cancer Enzalutamide resistance
Linkit:	http://www.sciencedirect.com/science/article/pii/S2352396423000658
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!